Biotechnology
Oxford Instruments launches Imaris 11: boosting research productivity with clear, workflow-driven image analysis
LONDON, Dec. 1, 2025 /PRNewswire/ -- Oxford Instruments announces the release of Imaris 11, the latest generation of its industry-leading 3D/4D microscopy image visualisation and analysis software. The new version introduces an intuitive Workflow system, enhanced batch processing, and advanced to...
2025-12-01 09:00
1208
Angel Yeast's 8,500-Ton Specialty Yeast Facility and New Brewing Microbial Pilot Platform Come Online
YICHANG, China, Nov. 28, 2025 /PRNewswire/ -- Angel Yeast
2025-11-28 20:58
2039
Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications
BEIJING, Nov. 28, 2025 /PRNewswire/ -- On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel ( Ina-cel) (tradename: YORWIDATM), has received new drug marketing a...
2025-11-28 20:52
1116
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 28, 2025 /PRNewswire/ -- Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been publ...
2025-11-28 12:32
1097
IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma
SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic mali...
2025-11-27 13:44
1005
Patronus Biotech receives grant to evaluate a novel malaria vaccine and adjuvant to support affordable access and use in global health
SINGAPORE, Nov. 27, 2025 /PRNewswire/ -- Patronus Biotech today announced a grant from the Gates Foundation to accelerate the development of its novel malaria vaccine and adjuvant program to support affordable access and use in global health. The funding will enable the evaluation of an innovativ...
2025-11-27 09:00
900
Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America
SINGAPORE, Nov. 26, 2025 /PRNewswire/ -- Prestige Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered inBuenos Aires, Argentina, with decades of experience in ...
2025-11-26 09:06
1396
Professor Chan Heum Park's Team at Hallym University Chuncheon Sacred Heart Hospital Sends Their Self-Developed "BioCabinet" to Space Aboard Nuri Rocket
SEOUL, South Korea, Nov. 26, 2025 /PRNewswire/ -- Chan Hum Park, M.D., Ph.D., Professor of Otolaryngology at Hallym University Chuncheon Sacred Heart Hospital and Director of the Nano-Bio Regenerative Medical Institute at Hallym University, leads the research team whose space biology payload, Bio...
2025-11-26 07:30
1052
Exyte completes Pharmaplan integration: A-to-Z execution in GMP facilities
* Pharmaplan fully integrated into Exyte, unifying biopharma engineering capabilities under one European organization. * Integrated setup drives strong client demand and a record order-intake level in 2025. * End-to-end EPC/EPCM delivery from feasibility to qualified handover across key lif...
2025-11-25 18:00
1094
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
CHENGDU, China, Nov. 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tiru...
2025-11-24 20:00
1214
GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
* Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology * Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea and HONG KONG, Nov. 24, 2025 /PRNewswire/ -- G...
2025-11-24 08:00
1349
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
PISCATAWAY, N.J., Nov. 22, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum London 2025 in the UK. This marks the Forum's second edition inEurope and the eighth consecutive G...
2025-11-22 20:28
1866
Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
MELBOURNE, Australia and KYOTO, Japan, Nov. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the official opening of Telix Manufacturing Solutions (TMS) inYokohama, Japan, the Company's first cyclotron facility in theAsia Pacific region (APAC...
2025-11-21 14:22
3131
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
* Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program * The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity ...
2025-11-21 13:46
1086
Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
* The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated Antigen (TAA) Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States, marking an important milestone in its global clinical dev...
2025-11-21 12:01
1204
PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting
IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01 (BAFFR-CAR T) have been accepted fo...
2025-11-20 23:12
1462
Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer
* The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. * The world's first gastric cancer perioperative regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting has met primary endpoints in its phase 3 cli...
2025-11-20 18:52
2280
Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs
SHANGHAI and HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune dis...
2025-11-20 10:56
981
WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Recognition in the CRDMO Industry
WuXi AppTec sets new benchmarks in strategic execution and technological
advancement, further strengthening its ability to support innovators worldwide
as they deliver breakthrough medicines for patients.
SAN ANTONIO, Nov. 20, 2025 /PRNewswire/ -- Frost & Sullivan
2025-11-20 10:00
824
BIOVOZ and the University of Auckland Join Forces to Lead the Next Frontier in Anti-Aging Research
From Ingredient Supplementation to Gene Regulation: BIOVOZ and the University of Auckland Pioneer a New Era in Beauty Science AUCKLAND, New Zealand, Nov. 19, 2025 /PRNewswire/ -- Leading beauty brand BIOVOZ has announced a strategic research partnership with the University ofAuckland, marking a ...
2025-11-19 15:02
691
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 291 media titles]
2026-01-05 12:14
Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 283 media titles]
2026-01-06 10:45
Panduit Announces Key Executive Appointments to Support Strategic Growth and Innovation
[Picked up by 281 media titles]
2026-01-07 10:00
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 280 media titles]
2026-01-01 10:00
Space Summit 2026 to Convene Global Leaders in Singapore to Address the Growing Space Economy
[Picked up by 272 media titles]
2026-01-07 15:27Most Read
China Daily Launches "China Bound" -- An English-Language Smart-Tourism Service Platform for International Travelers
2026-01-01 17:04
8931
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
2026-01-01 10:00
8139
Domestic GPU Leader Biren Technology Listed on Hong Kong Stock Exchange
2026-01-02 17:41
7546
